We're changing our website design on 27 August 2017.

Non-small cell lung cancer

The PBS subsidises crizotinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Crizotinib can be subsidised through the Pharmaceutical Benefit Scheme (PBS) under section 85 of the National Health Act 1953 for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC.

Patient eligibility

Patients must meet certain criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing crizotinib.

Applications

Initial treatment

Make all initial applications for authority approval to prescribe crizotinib for the treatment of Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC in writing and:

All applications must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 1 August 2017

This information was printed Tuesday 22 August 2017 from humanservices.gov.au/health-professionals/enablers/non-small-cell-lung-cancer It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.